Myozyme Market Report 2026

Myozyme Market Overview

• The Myozyme market growth in the historic period has been driven by recognition of pompe disease as a treatable condition, regulatory approvals for enzyme replacement therapies • Market expansion is supported by increasing investments in rare disease research, rising demand for next-generation enzyme therapies • Growth Driver: Increasing Incidence Of Rare Genetic Disorders Driving Market Growth • North America was the largest region in 2025.

What Is Covered Under Myozyme Market?

Myozyme is a powdered medication mixed into a solution for infusion (administered through an intravenous drip). It contains the active substance alglucosidase alfa, an enzyme replacement therapy used to treat Pompe disease, a rare inherited disorder. Myozyme helps replenish the deficient enzyme and improve the symptoms of the disease. The main indication for myozyme is the treatment of Pompe disease and other glycogen storage disorders. The treatment of Pompe disease focuses on enzyme replacement therapy (ERT), primarily with myozyme, which helps replace the deficient enzyme in patients with this rare genetic disorder. The end-users include hospitals, specialty clinics, research institutions, and homecare settings. Distribution channels consist of hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, and government and public health programs. The age groups treated are pediatric patients and adult patients.

What Is The Myozyme Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease research, rising demand for next-generation enzyme therapies, expansion of personalized treatment approaches, growing focus on pediatric rare disease management, advancements in biologics manufacturing technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on rare disease treatment solutions, growing demand for long-term pompe disease management, expansion of biologic drug manufacturing capabilities, enhanced patient access programs for orphan drugs.

Global Myozyme Market Segmentation

1) By Indication: Treatment of Pompe Disease, Other Glycogen Storage Disorders 2) By Age Group: Pediatric Patients, Adult Patients 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies, Government And Public health Programs 4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings

What Are The Drivers Of The Myozyme Market?

The increasing incidence of rare genetic disorders is expected to drive the growth of the myozyme market going forward. Rare genetic disorders are uncommon inherited conditions resulting from gene mutations, impacting only a small portion of the population. The increasing incidence of rare genetic disorders can be attributed to genetic mutations, improved genetic testing, and population growth. Myozyme helps manage the symptoms of Pompe disease by replacing the deficient enzyme, which can extend patients’ lives and improve their quality of life. As more individuals with Pompe disease receive treatment, it leads to longer survival rates and better health outcomes, further driving the demand for myozyme in managing these disorders. For instance, in July 2025, according to the Adult Polyglucosan Body Disease (APBD) Research Foundation, a US-based nonprofit organization dedicated solely to advancing research, a recent study on 1,4-alpha-glucan branching enzyme 1 (GBE1)-related rare genetic diseases updated the global prevalence estimate from 1 in 325,000 in 2022 to 1 in 236,000 in 2025, suggesting about 34,000 people worldwide could be affected, reflecting improved detection and data on these rare disorders. Therefore, the increasing incidence of rare genetic disorders is driving the growth of the myozyme industry. The rise in healthcare investment is expected to propel the growth of the myozyme market going forward. The investment in healthcare infrastructure is an allocation of resources to develop, improve, and maintain the physical, technological, and organizational systems necessary for effective healthcare delivery. Healthcare investment is increasing due to several factors, such as growing demand, pandemic preparedness, improving health outcomes, and the need for better access and equity. The rise in healthcare investment enhances the ability to develop specialized drugs such as myozyme and supports research, development, and accessibility of life-saving treatments for rare diseases. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the rise in healthcare investment is driving the myozyme industry. The rise in the adoption of telemedicine is expected to drive the growth of the myozyme market going forward. Telemedicine refers to using digital communication technologies to provide healthcare services remotely, including consultations, diagnoses, and treatment monitoring. The rise in the adoption of telemedicine is driven by factors such as increasing access to health care, greater convenience for patients, and significant cost savings for both providers and patients. Telemedicine enables more frequent and convenient consultations between patients and healthcare professionals. Early diagnosis of conditions like Pompe disease, which Myozyme treats, is crucial for effective treatment. Telemedicine can facilitate quicker diagnoses, thus increasing demand for Myozyme as more patients begin treatment earlier. For instance, in February 2025, according to the American Hospital Association, a US-based national organization representing and supporting US hospitals and health systems, in Q4 2023, more than 12.6% of Medicare beneficiaries utilized telehealth services. Therefore, the rising adoption of telemedicine is driving the growth of the myozyme industry.

Key Players In The Global Myozyme Market

Major companies operating in the myozyme market are Sanofi S.A.

Regional Insights

North America was the largest region in the myozyme market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Myozyme Market?

The myozyme market consists of the sale of pre-filled syringes, intravenous infusion, and vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myozyme Market Report 2026?

The myozyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myozyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.